CIK 0001035354 · Non-accelerated filer<br>Smaller reporting company
Eloxx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ELOX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 841368850
- Phone
- 781-577-5300
- Business address
- P.O. BOX 274, ARLINGTON, MA, 02476
- Former names
- Sevion Therapeutics, Inc., SENESCO TECHNOLOGIES INC, NAVA LEISURE USA INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-01-25 | MODUR VIJAY HEAD OF R&D | Grant or award · Stock Options (Right to Buy) | +30,000 | 30,000 | ||
| 2022-07-01 | Androski Lindsay Director | Grant or award · Stock Options (Right to Buy) | +40,000 | 40,000 | ||
| 2022-06-15 | Walts Alan Edmund Director | Grant or award · Stock Options (Right to Buy) | +20,000 | 20,000 | ||
| 2022-06-15 | Veinrib Gadi Director | Grant or award · Stock Options (Right to Buy) | +20,000 | 20,000 | ||
| 2022-06-15 | Seehra Jasbir Director | Grant or award · Stock Options (Right to Buy) | +20,000 | 20,000 | ||
| 2022-06-15 | Rubin Steven D Director | Grant or award · Stock Options (Right to Buy) | +20,000 | 20,000 | ||
| 2022-06-15 | PAREKH RAJESH B Director | Grant or award · Stock Options (Right to Buy) | +20,000 | 20,000 | ||
| 2022-06-15 | Nussbaum Ran Director | Grant or award · Stock Options (Right to Buy) | +20,000 | 20,000 | ||
| 2022-06-15 | Kariv Tomer Director | Grant or award · Stock Options (Right to Buy) | +20,000 | 20,000 | ||
| 2022-06-15 | Avnur Zafrira Director | Grant or award · Stock Options (Right to Buy) | +20,000 | 20,000 | ||
| 2022-02-06 | Aggarwal Sumit President and CEO | Grant or award · Stock Option (Right to Buy) | +42,790 | 42,790 | ||
| 2021-12-01 | Walts Alan Edmund Director | Option exercise | +37,695 | 37,695 | ||
| 2021-12-01 | Walts Alan Edmund Director | Option exercise · Restricted Stock Units | −37,695 | 0 | ||
| 2021-12-01 | Aggarwal Sumit PRESIDENT AND CEO | Option exercise | +279,158 | 279,158 | ||
| 2021-12-01 | Aggarwal Sumit PRESIDENT AND CEO | Shares withheld for taxes | −81,933 | $0.72 | $59K | 197,225 |
| 2021-12-01 | Aggarwal Sumit PRESIDENT AND CEO | Option exercise · Restricted Stock Units | −279,158 | 0 | ||
| 2021-12-01 | MODUR VIJAY HEAD OF R&D | Option exercise | +219,326 | 219,326 | ||
| 2021-12-01 | MODUR VIJAY HEAD OF R&D | Shares withheld for taxes | −64,373 | $0.72 | $46K | 154,953 |
| 2021-12-01 | MODUR VIJAY HEAD OF R&D | Option exercise · Restricted Stock Units | −219,326 | 0 | ||
| 2021-11-29 | Geffken Daniel E. INTERIM CFO | Purchase | +50,000 | $0.72 | $36K | 50,000 |
Page 4 of 11 · 206 trades